Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells.

Cash J, Korchnak A, Gorman J, Tandon Y, Fraizer G.

Oncol Rep. 2007 Jun;17(6):1413-9.

PMID:
17487399
2.

Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.

Zaia A, Fraizer GC, Piantanelli L, Saunders GF.

Anticancer Res. 2001 Jan-Feb;21(1A):1-10.

PMID:
11299720
3.

Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.

Graham K, Li W, Williams BR, Fraizer G.

Gene Expr. 2006;13(1):1-14.

4.

Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.

Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS, Bulla M, Royer-Pokora B.

J Am Soc Nephrol. 2007 Mar;18(3):719-29. Epub 2007 Jan 31.

5.

Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.

Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M.

Int J Oncol. 2004 Mar;24(3):461-71.

PMID:
14767530
6.

Hormone treatment enhances WT1 activation of Renilla luciferase constructs in LNCaP cells.

Hanson J, Reese J, Gorman J, Cash J, Fraizer G.

Front Biosci. 2007 Jan 1;12:1387-94.

PMID:
17127389
7.

Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).

Ling MT, Lau TC, Zhou C, Chua CW, Kwok WK, Wang Q, Wang X, Wong YC.

Carcinogenesis. 2005 Oct;26(10):1668-76. Epub 2005 May 19.

PMID:
15905202
8.

Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.

Hanson J, Gorman J, Reese J, Fraizer G.

Front Biosci. 2007 Jan 1;12:2279-90.

9.

Androgens down-regulate the expression of the human homologue of paternally expressed gene-3 in the prostatic adenocarcinoma cell line LNCaP.

Ulrix W, Swinnen JV, Heyns W, Verhoeven G.

Mol Cell Endocrinol. 1999 Sep 10;155(1-2):69-76.

PMID:
10580840
10.

Transcriptional regulation of PDGF-A and TGF-beta by +KTS WT1 deletion mutants and a mutant mimicking Denys-Drash syndrome.

Jin DK, Kang SJ, Kim SJ, Bang EH, Hwang HZ, Tadokoro K, Yamada M, Kohsaka T.

Ren Fail. 1999 Nov;21(6):685-94.

PMID:
10586431
11.

Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.

Patek CE, Fleming S, Miles CG, Bellamy CO, Ladomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML.

Hum Mol Genet. 2003 Sep 15;12(18):2379-94. Epub 2003 Jul 22.

PMID:
12915483
12.

Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.

Tesan T, Gustavsson H, Welén K, Damber JE.

BJU Int. 2008 Sep;102(8):1034-9. doi: 10.1111/j.1464-410X.2008.07768.x. Epub 2008 May 16.

13.

Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.

Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, Nilsson E, Otterbein LE, Härkönen P, Persson JL.

J Natl Cancer Inst. 2008 Jul 16;100(14):1022-36. doi: 10.1093/jnci/djn214. Epub 2008 Jul 8.

14.

Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells.

Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M.

Cancer Res. 2004 Jan 15;64(2):631-8.

15.

Analysis of WT1 target gene expression in stably transfected cell lines.

Thäte C, Englert C, Gessler M.

Oncogene. 1998 Sep 10;17(10):1287-94.

16.

Highly tumorigenic human androgen receptor-positive prostate cancer cells overexpress angiogenin.

Kawada M, Inoue H, Arakawa M, Takamoto K, Masuda T, Ikeda D.

Cancer Sci. 2007 Mar;98(3):350-6.

17.

A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.

Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schönfelder G.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1406-11. Epub 2006 Jan 23.

18.

An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.

Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, Hobisch A, Culig Z.

Eur J Cancer. 2004 May;40(7):1066-72.

PMID:
15093584
19.

EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP.

Sundareshan P, Nagle RB, Bowden GT.

Prostate. 1999 Aug 1;40(3):159-66.

PMID:
10398277
20.

Supplemental Content

Support Center